Saturday, August 5th

 3-7pm CHECK-IN and REGISTRATION Conference Office @ 10 Buick St. Room G18
 Evening The bar at the Eastern Standard, Hotel Commonwealth, 528 Commonwealth Avenue (take Green Line inbound to Kenmore Square). – Unofficial event.

Sunday, August 6th

8.15-8.30am	WELCOME Tribute to Joe Korn	C Black and R Lafyatis R Simms
8.30-10	Session I – Stem Cell Biology in Vascular and Fibrotic Disease Moderator: R Strieter Keynote: J Huard - Regenerative medicine based on muscle derived stem cells: Potential for tissue regeneration and repair M Kuwana - Circulating endothelial progenitors as a therapeutic target for scleroderma vascular disease C Dong - Deficient repair - the culprit of scleroderma vascular lesion formation?	
10-10.30	Coffee Break	
10.30-12.30pm	Session II – Vascular Disease in Systemic Sclerosis Moderator: H Farber Keynote: M. Rabinovitch - Infection, Inflammation Mts1 and Pulmonary Hypertension K Pritchard - D-4F, an ApoA-I mimetic, decreases inflammation and fibrosis and increases angiogenic responses in the myocardium of tight skin mice N Flavahan - The cold facts about peripheral vasospasm B Khaw - Molecular Imaging of vascular injury	
10 00 1 00	lunch	

12.30-1.30 Lunch

1.30-3.30	Breakout Session I A. Hurdles, networks, funding: Where should we be going? – CGS511 Moderator: S Jimenez/F Arnett E Gretz – National Institutes of Health L Evnin – Scleroderma Research Foundation E Gravallese – Arthritis Foundation J Blint – Scleroderma Foundation	
	 B. Animal Models - CGS505 Moderator: S Clark/H Gardner C Denton - Inducible disruption of TGFbeta signalling in fibroblasts in vivo R Lafyatis - Complex cytokine regulation of Tsk1 pathology P Christner/J Gentiletti - The fibrotic and immunologic facets of the Tsk2 mouse C Feghali-Bostwick S Sonnylal - CTGF overexpressing mice: A model for human scleroderma 	
3.30-4	Tea Break	
4-6	Session III – Inflammation and Vascular Injury Moderator: B Kahaleh/S Schwartz Keynote: P Libby - Inflammation and the regulation of arterial extracellular matrix metabolism O Distler - The impaired angiogenesis in systemic sclerosis S Schwartz - The vasculopathy of scleroderma S Jimenez – Role of allograft inflammatory factor 1 (AIF-1) in the pathogenesis of SSc vasculopathy	
6-7.30	Welcome Reception – Agganis Arena Burke Club Room	

Monday, August 7th

 8.30-10.00am Session IV – Autoimmune Dysregulation in Systemic Sclerosis Moderator: A Marshak-Rothstein Keynote: A Rosen - Autoimmunity in scleroderma T Radstake - Toll-like receptors in systemic sclerosis, new light on a ancient system! T Tedder - Are B lymphocytes contributing to systemic sclerosis pathogenesis?

10-10.30 Coffee Break

 10.30-12.00pm Session V – T-cell Regulation and Fibrosis Moderator: M Kuwana Keynote: R Flavell - Regulation of immunity and autoimmunity by TGFβ
 T MacDonald – Smad 7 control of TGFβ responses in the gut
 C Buckley – Defining a role for fibroblasts in the persistence of chronic inflammation

- 12-1 Lunch
- 1-1.30 Poster Viewing 18th Floor Lounge, 10 Buick Street. Authors stand by posters

1.30-3 Poster Session – Dance Theatre - Top ranking posters orally presented Moderator: P Clements P Fernandez – Adenosine modulates dermal fibrogenesis A Bujor - Akt positively regulates collagen in dermal fibroblasts via a Smad3 independent pathway A Ghatnekar - The Role of Gata3 as a regulator of ECM homeostasis in SSc A Ghosh - Peroxisome proliferator-activated receptor-y (PPAR-y) inhibits collagen gene expression: implications for Fibrosis Y Pare - CD4+ CD8+ double positive (DP) T cells with very high IL-4 production potential are present in lesional skin of systemic sclerosis (SSc) patients

T Rodriguez-Reyna - Rate of skin thickness progression in early systemic sclerosis with diffuse cutaneous involvement: Associations with organ involvement and 5 year survival D Abraham (V Rajkumar) – PDGFB receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing

- 3-3.15 Tea break
- 3.15-4.45 Session VI Fibrotic Mediators I Moderator: T MacDonald Keynote: P ten Dijke - TGFβ receptor signal transduction M Trojanowska - Fibroblast signaling in scleroderma J Pearson - Endothelin and fibrosis
- 5.00-7 Breakout Session II A. Immunomodulators and Fibrotic Disease – CGS511 Moderator: F Wigley

New therapeutic agents in scleroderma:

C Denton – Mycophenolate mofetil in diffuse scleroderma

E Smith – Sirolimus (Rapamycin)

R Silver - Anti-chemokine therapy (MCP-1/CCR2)

L Hummers – Intravenous gammaglobulin

R Lafyatis – Anti-B cell therapy (rituximab)

B. Chronic graft vs. host disease modeling of SSc – CGS505 Moderator: A Gilliam

A Gilliam - Triggers of fibrosing disease in GVHD - why sclerodermatous disease rather than lupus-like epithelial injury? W Shlomchik - Roles of antigen, antigen presenting cells and naive CD4 cells in murine chronic GVHD

A Aliprantis - The role of T-bet in scleroderma and the molecular phenotype of murine chronic GVHD

Tuesday, August 8th

8.30-10.30am	Session VII – Tissue Fibrosis: Cellular Pathogenesis Moderator: J Varga
	T Krieg - Mechanism of fibroblast activation and the role of cell matrix contacts
	S Phan - Transcriptional regulation of myofibroblast differentiation H Chang - Site specific differentiation and positional memory of fibroblasts
	E Leof - TGF-beta signaling targets in fibrotic diseases
10.30-11	Coffee Break
11-12.30pm	Session VIII – Fibrotic Mediators
	Moderator: D Abraham D Brigstock - Connective tissue growth factor: Structure, function, and role in fibrosis
	K Lyons - In vivo studies of CCN1/Cyr61 and CCN2/CTGF function in connective tissues and vasculature
	J Bonner - PDGF Signaling in Chronic Airway Remodeling and Fibrosis
12.30-1.30	Lunch
2-4	Session IX – Pulmonary Fibrosis/Pathogenesis Moderators: A Wells /K Brown
	Keynote: J Elias - Transgenic investigations of Th2 and TGF-beta1- induced tissue fibrosis
	V Thannickal - Novel insights into myofibroblast activation and survival N Kaminski - Microarray analysis of Human Lung Fibrosis - from profiles
	to pathways R Strieter - The role of circulating mesenchymal progenitor cells in pulmonary fibrosis
4-4.30	Tea Break

4.30-6.30 Breakout Session III - CGS511

A. How do we block TGFβ in scleroderma?
Moderator: M Trojanowska
S Violette - The alphavbeta6 integrin: A novel therapeutic target for lung and kidney fibrosis
A Protter - TBA
J McPherson - Progress in the clinical development of anti-TGF-beta antibodies for the treatment of fibrotic diseases

B. Gene expression profiles, what do they tell us? - CGS505

Moderator: C Feghali-Bostwick
M Whitfield - Molecular portraits of scleroderma skin
F Tan - The next step after differential gene expression
H Gardner - Gene profiling in SSc: Fibroblasts forget where they came from and other results

7-9 BANQUET – Agganis Arena Burke Club Room Speaker: Dr. Don Berwick

Wednesday, August 9th

 8.30-10.30am Session X – Pulmonary Fibrosis/Clinical Moderator: R Du Bois Keynote: A Wells - Pulmonary fibrosis in scleroderma: How clinical science can refine management J Goldin - Quantitative Image Analysis of HRCT: predictor and measure of treatment efficacy J Seibold - Clinical applications of endothelin antagonists in scleroderma K Brown - Pulmonary fibrosis: Clinical insights into disease mechanism

10.30-10.45 Coffee Break

10.45-12.30pm Session XI – Genetic Analyses in Scleroderma Moderator: F Arnett Keynote: M Seldin - Understanding and application of population genetic structure to problems in medicine and autoimmunity M Mayes - Scleroderma genetics: Where we are and where we want to be R Du Bois - Genetics of lung fibrosis: It's all in the genotype K Welsh - Scleroderma genetics worldwide: One disease, many incorrect papers- or many diseases? Do we have or can we get the answer? 12.30-1.30 Lunch 1.30-3.30 Session XII– Outcome Measures Moderator: M Matucci-Cerinic A Tyndall - Report from the EUSTAR Minimal Essential Data Set (MEDS) data base D Furst - Progress at OMERACT toward combined measures of response in SSc: Renal disease, pulmonary disease and early efforts at a combined index of response

D Khanna - Patient-reported outcomes in scleroderma P Merkel – Outcome measures for scleroderma clinical trials: A data-driven re-evaluation